Medical Device Global Market Access

Singapore's Health Sciences Authority (HSA) has released its finalized 'Best Practices Guide for Medical Device Cybersecurity' (GL-10-R1), effective August 17, 2026. This episode explores the guide's three core principles—secure-by-design, shared responsibility, and transparency—and outlines their impact on manufacturers and healthcare providers. We discuss how these recommendations affect the total product lifecycle, from pre-market design to post-market surveillance, and provide actionable steps for regulatory, quality, and market-access teams to align with these new expectations. Key Questions: - What is the scope of Singapore HSA's new cybersecurity guide, GL-10-R1? - When does the new guidance become effective? - How does the 'secure-by-design' principle impact device development? - What does 'shared responsibility' mean for manufacturers and healthcare providers? - Why is transparency, including the use of an SBOM, now a best practice in Singapore? - Is compliance with this guide mandatory for pre-market device registration? - What are the expectations for post-market cybersecurity surveillance? - How can our team perform a gap analysis against these new recommendations? - What documentation changes are needed to align with the HSA's TPLC approach? Sources: - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGfeD51Gc0b8bXrqivrB1f_yGJ-oReepm1pwtUbCHvMVDMzBSGpP10xIL5VkgYs4NDhlHZU3XQ1R8FZ9pGI_k2Qf7XTrUr0r2h7hcYZTYd86gp2yGgNTzQG7bND_5OZSxuH2Wzf4ErQYG27cGNwR1hW2wJh75gaeyfNSCUJyTuDtr2TWgfKOs_-fS9Ws5c4juzk_x_xMeTh7-XsoDd3k-8EtMSXRuQIMVrXj2e-VHjgzzKeQGarhIAeSQCOpGA= - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFxa4zvDJJCRocH1oHTSnh2B2AAAHJFDoujOt2pFVcWf4NqOVo-qqozSujWIfe4EneSoW2xdyqpEItPSjWNBRdQGjhhYBRGThO9JaIHCPHC1PWye_Db_zmovuHxhdoWWNbfB-L0mYtRE6HxFgqDWHgNBnc441qzL_QrqwExqXPJRQNH6dmtzg== How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping you navigate complex requirements like Singapore's new cybersecurity guidance. We specialize in developing robust regulatory strategies, compiling and submitting technical dossiers, and implementing continuous regulatory monitoring to ensure your products remain compliant. Our combination of local expertise in over 30 markets and advanced AI technology streamlines the entire market access process, from initial gap analysis to post-market surveillance. For support with your global regulatory needs, visit us at https://pureglobal.com, contact us at [email protected], or explore our free AI tools and regulatory database at https://pureglobal.ai.

Mexico's health authority, COFEPRIS, has launched the Medical Device Sanitary Registry Viewer, a public digital tool for verifying device registrations. This episode explores how this platform, launched on August 20, 2026, enhances market transparency and simplifies compliance. We discuss how the tool works, its impact on manufacturers, distributors, and healthcare providers, and outline practical steps for regulatory teams to adapt to this new environment. Key Questions: - What is the new COFEPRIS Medical Device Sanitary Registry Viewer? - How does this public database impact market transparency in Mexico? - What specific information can be found using the new digital tool? - How does the viewer help combat counterfeit or unregistered medical devices? - What are the implications for manufacturers holding sanitary registrations? - How should distributors and importers change their compliance processes? - What steps should regulatory teams take to verify their product portfolios? - How does this initiative fit into COFEPRIS's broader digitalization strategy? Sources: - https://mexicobusiness.news/health/news/cofepris-opens-public-viewer-for-medical-device-registries How Pure Global can help: Pure Global helps MedTech and IVD companies navigate complex regulatory landscapes like Mexico's. Our local experts and advanced AI tools streamline market access, from initial strategy and technical dossier submission to acting as your official Local Representative. We ensure your registrations remain compliant amidst changes like the new COFEPRIS digital viewer through continuous regulatory monitoring. Whether you're a startup or a multinational, we accelerate your path to market. Learn more about our services, free AI tools, and global database at https://pureglobal.ai, or contact us at [email protected] and https://pureglobal.com.

India's CDSCO has amended the Medical Devices Rules, 2017, effective August 24, 2024, removing the 'loan licence' requirement for manufacturers who outsource device sterilization. This episode explains the amendment, details the new mandatory labeling requirements for sterilized products, and outlines the practical steps that regulatory and quality teams must take during the six-month transition period to ensure compliance. Key Questions: - What was the 'loan licence' requirement for medical device sterilization in India? - How does the CDSCO's August 2024 amendment change the rules for outsourced sterilization? - Who is most affected by this regulatory update? - What are the new, specific labeling requirements for sterile medical devices? - What is the deadline for manufacturers to comply with these new labeling rules? - How does this change impact the relationship between manufacturers and third-party sterilization facilities? - What practical steps should regulatory teams take to ensure compliance? - Does this amendment simplify the market access process in India? Sources: - https://www.livemint.com/industry/pharma/govt-eases-medical-device-rules-speeds-access-to-eu-approved-products-11724508681177.html How Pure Global can help: Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. For companies navigating changes like India's new sterilization rules, we provide expert regulatory strategy, technical dossier preparation, and local representation in over 30 markets. Our team helps ensure your labeling, QMS, and supplier agreements are fully compliant, minimizing delays and risks. Leverage our advanced AI tools and data-driven insights to manage submissions efficiently and maintain your market presence. Contact us at [email protected] or visit https://pureglobal.com. Explore our free AI tools and database at https://pureglobal.ai.

The EU Notified Body landscape was shaken in August 2024 with announcements that the National Standards Authority of Ireland (NSAI) will exit its MDR designation by 2026 and TÜV NORD Scandinavia has filed for bankruptcy. This episode breaks down the immediate impact on manufacturers certified by these bodies, the broader implications for Notified Body capacity under the MDR, and the critical strategic steps regulatory teams must take now to protect their EU market access. Key Questions: - What were the specific announcements from NSAI and TÜV NORD Scandinavia in August 2024? - Why is the National Standards Authority of Ireland (NSAI) exiting the MDR business by 2026? - What led to the bankruptcy of TÜV NORD Scandinavia so soon after its acquisition? - If your device is certified by NSAI or TÜV NORD, what are your immediate obligations? - How does this reduction in Notified Bodies impact overall MDR certification capacity in the EU? - What are the key differences between an 'orderly exit' and a bankruptcy for a Notified Body? - What practical steps should regulatory teams take right now to secure their CE marking? - How can manufacturers vet the long-term stability of a potential new Notified Body partner? Sources: - https://medtech.citeline.com/MT153434/NSAI-Will-Make-Orderly-Exit-From-MDR-Notified-Body-Business - https://medtech.citeline.com/MT153424/Low-Demand-Causes-TV-NORD-Scandinavia-Bankruptcy-Just-7-Months-After-Purchase How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech and IVD companies navigate complex market access challenges like unexpected Notified Body changes. Our experts can develop an immediate-response strategy, manage the complex process of transferring your CE certification to a new Notified Body, and ensure your technical documentation is prepared for a smooth transition. We act as your local representative and leverage advanced AI tools to streamline submissions and monitor regulatory shifts, ensuring your market presence is secure. Contact us at [email protected] or visit https://pureglobal.com to learn more. Explore our free AI regulatory tools and device database at https://pureglobal.ai.

Japan's PMDA and AdvaMed are hosting a free online workshop on September 1, 2026, for U.S.-based small and mid-sized medtech companies. This episode breaks down the significance of this direct engagement opportunity, covering the key topics on the agenda—including Japan's regulatory framework, scientific advice process, and review pathways. We discuss the strategic value for manufacturers and provide practical steps your regulatory and market access teams should take to maximize the benefits of this event and de-risk your entry into the Japanese market. Key Questions: - What is the upcoming PMDA and AdvaMed workshop and who should attend? - How can U.S. medtech SMEs benefit from this direct engagement with Japanese regulators? - What specific topics will the PMDA cover regarding Japan's regulatory framework? - Why is the scientific advice process in Japan crucial for a successful submission? - What are the key steps in the PMDA's medical device review process? - How can this event help de-risk your company's entry into the Japanese market? - What practical actions should your team take before and after the September 1, 2026 workshop? - What makes the Japanese medical device market both attractive and challenging? Sources: - https://www.advamed.org/events/entering-the-japanese-medical-device-market-regulatory-pathways-consultation-opportunities-and-practical-insights/ How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech and IVD companies navigate complex markets like Japan. Our local experts and advanced AI tools streamline market access, from developing regulatory strategy and compiling technical dossiers to acting as your in-country representative. We help you get your products approved and maintain compliance efficiently, turning regulatory hurdles into market opportunities. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI regulatory tools and product database at https://pureglobal.ai to accelerate your global expansion.

This episode examines the UK MHRA's Device Safety Information alert (DSI/2026/008), issued on August 18, 2026, which advises against the use of rectal catheters (gas/colic relievers) in infants. We explore why the MHRA took this precautionary action based on a lack of safety and efficacy data, rather than direct adverse event reports. The discussion focuses on the critical post-market surveillance lessons for manufacturers of direct-to-consumer medical devices, particularly those intended for vulnerable populations like children. Key Questions: - What is the UK MHRA's DSI/2026/008 and why was it issued? - Why are rectal catheters (gas/colic relievers) now considered unsafe for infants in the UK? - What does this alert mean for manufacturers and distributors of direct-to-consumer pediatric devices? - How does this MHRA action highlight the importance of proactive post-market surveillance? - What specific evidence did the MHRA find lacking for these devices? - What are the immediate steps regulatory and quality teams should take in response to this type of alert? - How can you strengthen your clinical data for devices intended for vulnerable populations? - Is this alert based on reported injuries, or is it a precautionary measure? Sources: - https://www.gov.uk/government/publications/rectal-catheters-sold-for-personal-use-gas-and-colic-relievers-do-not-use-in-infants-including-for-the-treatment-of-colic-gas-related-discomfort-or-constipation-dsi2026008 - https://www.rpharms.com/resources/news-and-updates/update-all-rectal-catheters-gas-and-colic-relievers-do-not-use-in-infants How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech companies navigating complex global markets like the UK. Our experts can help you develop a robust post-market surveillance (PMS) and post-market clinical follow-up (PMCF) strategy to ensure your products meet evolving regulatory expectations for safety and efficacy, especially for high-risk or vulnerable populations. We use advanced AI to compile technical dossiers, monitor regulatory changes, and ensure your labeling and clinical evidence are compliant. Whether you need to revise your regulatory strategy or manage submissions, we streamline the process for faster, more reliable market access. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and device database at https://pureglobal.ai.

Brazil's ANVISA has opened a new pathway for innovative, high-risk medical devices. On August 5, 2026, the agency published Call Notice 5/2026, inviting manufacturers of Class III and IV devices with novel technologies to apply for a collaborative regulatory evaluation pilot program. This episode details the program's objectives, strict eligibility criteria (including AI-based devices and new biomaterials), the critical 30-day application window, and the strategic advantages of early engagement with ANVISA for accelerating market access in Brazil. Key Questions: - What is ANVISA's innovative medical device pilot program announced in August 2026? - Which types of high-risk medical devices are eligible to apply? - What are the specific eligibility criteria, such as the use of AI or new biomaterials? - What is the application deadline for Call Notice 5/2026? - How does this pilot program differ from the standard ANVISA review process? - What are the strategic benefits of participating in this collaborative evaluation? - What documentation is required for the application? - How can manufacturers prepare for this opportunity to accelerate market access in Brazil? Sources: - https://www.gov.br/anvisa/pt-br/assuntos/noticias/2026/anvisa-lanca-novo-edital-para-avaliacao-regulatoria-de-dispositivos-medicos-inovadores - https://www.sobel.com/innovative-medical-devices-in-brazil-how-anvisas-2026-pilot-program-works/ - https://www.demarest.com.br/en/insights/client-alerts/opportunity-anvisa-to-select-innovative-medical-device-projects-for-regulatory-assessment How Pure Global can help: Pure Global streamlines global market access for MedTech and IVD companies. With local experts in Brazil, we can act as your official representative and guide your regulatory strategy for complex products, including submissions for specialized programs like ANVISA's innovative device pilot. Our AI-powered platform helps prepare technical dossiers efficiently, ensuring your submission is comprehensive and competitive. We manage the entire lifecycle, from initial strategy to post-market surveillance, helping you enter and thrive in over 30 markets. Visit us at https://pureglobal.com, contact us at [email protected], or explore our free AI tools and database at https://pureglobal.ai.

The Saudi Food and Drug Authority (SFDA) is increasing its focus on the biological evaluation of medical devices, highlighted by its upcoming workshop on August 10, 2026. This episode explores what this means for manufacturers seeking market access in Saudi Arabia. We discuss the SFDA's alignment with ISO 10993, the critical importance of a risk-based approach, and the need for a comprehensive Biological Evaluation Report (BER) in your technical dossier. Learn practical steps to review your existing data, manage material changes, and prepare for heightened regulatory scrutiny to avoid submission delays. Key Questions: - What does the SFDA's August 10, 2026 workshop on biocompatibility signal to manufacturers? - How does this align with global standards like ISO 10993? - Which types of medical devices are most affected by this increased scrutiny? - What are the essential components of a Biological Evaluation Report (BER) that will satisfy SFDA reviewers? - Why is a risk-based approach critical for your biocompatibility documentation? - What common gaps are found in biocompatibility submissions to the SFDA? - How should you prepare your technical dossier for future submissions to Saudi Arabia? - What practical steps can your regulatory team take today to ensure compliance? Sources: - https://www.sfda.gov.sa/en/workshop/Introduction-to-Medical-Device-Executive-Regulation-and-Medical-Device-Requirements-Update How Pure Global can help: Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. For Saudi Arabia, we provide local representation, develop efficient regulatory strategies, and use advanced AI to compile and manage technical dossiers that meet SFDA expectations, including robust biocompatibility evaluations. Our experts help you navigate complex requirements to ensure your submissions are complete and compliant, minimizing delays. To learn how we can accelerate your market entry, visit us at https://pureglobal.com, contact us at [email protected], or explore our free AI tools and database at https://pureglobal.ai.

This episode details the US FDA's discussion paper on regulating medical devices incorporating Generative Artificial Intelligence (GenAI), released on August 18, 2026. We cover the key areas where the FDA is seeking input, including risk assessment, premarket evaluation, and postmarket monitoring for GenAI-enabled devices. We also emphasize the critical October 19, 2026, deadline for submitting feedback and provide practical steps for manufacturers to prepare and respond. Key Questions: - What is the FDA's new discussion paper on Generative AI in medical devices? - Why is the FDA seeking public feedback before issuing guidance? - What are the key risk assessment challenges for GenAI-enabled devices? - How might premarket submission requirements change for these products? - What postmarket surveillance obligations is the FDA considering? - Who is affected by this new regulatory exploration? - What is the deadline for submitting comments to the FDA? - What practical steps should regulatory and R&D teams take right now? - How does GenAI differ from traditional AI/ML in the eyes of regulators? Sources: - https://www.fda.gov/news-events/press-announcements/fda-seeks-public-feedback-inform-regulatory-approach-generative-ai-enabled-medical-devices - https://www.fda.gov/medical-devices/digital-health-center-excellence/considerations-regulation-generative-ai-enabled-medical-devices-discussion-paper-and-request-feedback How Pure Global can help: Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We help you develop efficient regulatory strategies and prepare technical dossiers for submission to authorities like the FDA, especially for novel technologies like AI/ML and GenAI. Our experts can help you analyze new discussion papers, formulate feedback, and perform gap analyses to ensure your quality and development processes are aligned with future requirements. With a presence in over 30 markets, we streamline global market access. Learn more about our AI-powered tools and global database at https://pureglobal.ai, or contact us at [email protected] and https://pureglobal.com.

This episode covers the U.S. FDA's proposed rule from August 14, 2026, which aims to classify a specific list of medical device accessories as Class I. We discuss how this change would exempt these products from 510(k) premarket notification, significantly reducing the regulatory burden for manufacturers. The host details the implications for market access strategy, the cost and time savings, and highlights the critical public comment deadline of October 16, 2026, urging listeners to review the list and provide feedback. Key Questions: - What is the FDA's proposed rule from August 14, 2026, regarding medical device accessories? - Which types of accessories might be reclassified as Class I and become 510(k)-exempt? - How does this proposal change the regulatory pathway for affected devices in the U.S.? - What is the deadline for submitting public comments on this proposed rule? - What are the primary benefits for manufacturers if this rule is finalized? - How can companies determine if their accessory products are on the FDA's proposed list? - What practical steps should regulatory and quality teams take right now? - Why is this considered a significant de-regulatory action by the FDA? Sources: - https://www.federalregister.gov/documents/2026/08/18/2026-17828/medical-devices-classification-of-accessories-distinct-from-other-devices-proposed-list-of - https://www.fda.gov/medical-devices/cdrh-new-news-and-updates/cdrh-new-news-and-updates How Pure Global can help: Navigating regulatory shifts like the FDA's proposed rule on accessories requires expertise and strategic planning. Pure Global offers end-to-end consulting for MedTech and IVD companies, helping you develop efficient pathways for U.S. and global regulatory approval. Our team uses advanced AI and data tools to compile technical dossiers, monitor regulatory changes, and identify the best markets for expansion. Whether you need help submitting public comments, adjusting your regulatory strategy, or managing global registrations, we provide the local expertise and technology-driven solutions to accelerate your market access. Contact us at [email protected] or visit https://pureglobal.com. Explore our free AI tools and regulatory database at https://pureglobal.ai.

The Saudi Food and Drug Authority (SFDA) has implemented new mandatory requirements for medical device advertising, effective July 20, 2026. This episode breaks down the key provisions of the new guidance, MDS-REQ 8, which mandates pre-approval from the SFDA for all advertising, awareness, and charitable campaigns. We explore the broad scope of materials covered—from social media to brochures—the official submission process through the GHAD electronic system, and the critical responsibilities of manufacturers, authorized representatives, and distributors. Tune in for practical steps your regulatory and marketing teams must take to ensure compliance and maintain market access in Saudi Arabia. Key Questions: - What is the new SFDA requirement MDS-REQ 8 for medical device advertising? - When did these new advertising rules become effective in Saudi Arabia? - Which types of promotional materials require SFDA approval? - Who is responsible for obtaining the advertising license for medical devices? - What is the process for submitting advertising materials to the SFDA via the GHAD system? - How does this regulation impact social media and digital marketing campaigns? - What are the key compliance conditions for advertising content to avoid rejection? - What immediate steps should regulatory and marketing teams take to align with MDS-REQ 8? - How can manufacturers avoid penalties for non-compliant advertising in the Kingdom? Sources: - https://www.sfda.gov.sa/en/laws-regulations?type=338 How Pure Global can help: Pure Global provides end-to-end regulatory support for MedTech and IVD companies seeking to navigate complex markets like Saudi Arabia. Our local experts can act as your official Saudi Authorized Representative, manage your advertising submissions under MDS-REQ 8, and develop a comprehensive regulatory strategy to ensure compliance and speed to market. We combine in-country expertise with advanced AI tools to streamline technical dossier preparation and submission management. To learn how we can help you access over 30 global markets efficiently, contact us at [email protected] or visit https://pureglobal.com. Explore our free AI regulatory database and tools at https://pureglobal.ai.

The U.S. Centers for Medicare & Medicaid Services (CMS) has introduced a major policy change with the new Regulatory Alignment for Predictable and Immediate Device (RAPID) Coverage Pathway. Announced in a procedural notice on August 7, 2026, this pathway aims to significantly reduce the delay between FDA market authorization and a national Medicare coverage decision for eligible FDA Breakthrough-designated devices. This episode breaks down the eligibility criteria for Class II and III devices, the plan for simultaneous FDA and CMS decisions, and the critical public comment deadline of October 10, 2026. We explore what this means for innovative device manufacturers and provide practical steps for navigating this new reimbursement landscape. Key Questions: - What is the new CMS RAPID Coverage Pathway and what problem does it solve? - How does the RAPID pathway propose to align FDA authorization with Medicare coverage decisions? - Which specific types of medical devices are eligible for this expedited reimbursement program? - What was announced in the CMS procedural notice on August 7, 2026? - What is the significance of the October 10, 2026 deadline for public comments? - How should manufacturers adjust their evidence generation strategy to meet both FDA and CMS requirements? - What are the key differences between the FDA's 'safe and effective' standard and CMS's 'reasonable and necessary' criteria? - What practical steps should regulatory and market access teams take to prepare for the RAPID pathway? Sources: - https://www.cms.gov/newsroom/fact-sheets/regulatory-alignment-predictable-immediate-device-coverage-pathway-cms-3487-nc-procedural-notice - https://www.aha.org/news/headline/2026-08-07-cms-releases-notice-pathway-expediting-access-certain-medical-devices-medicare - https://www.hklaw.com/en/insights/publications/2026/08/rapid-coverage-pathway-comments-due-october-10-2026 - https://www.acrinews.org/archives/2026/August/CMS-Proposes-RAPID-Pathway-for-Faster-Device-Coverage - https://www.managedhealthcareexecutive.com/view/cms-and-fda-propose-rapid-medicare-coverage-pathway-for-breakthrough-devices - https://www.worktraining.com/news/cms-proposes-rapid-pathway-for-accelerated-medicare-coverage-of-innovative-medical-devices/ - https://www.federalregister.gov/documents/2026/08/11/2026-17389/medicare-program-regulatory-alignment-for-predictable-and-immediate-device-rapid-coverage-pathway How Pure Global can help: Navigating complex reimbursement pathways like the CMS RAPID program requires a strategic approach to both regulatory approval and market access. Pure Global provides end-to-end consulting for MedTech companies, developing efficient regulatory strategies that align with reimbursement requirements from the earliest stages. Our experts help you prepare for parallel engagement with bodies like the FDA and CMS, ensuring your technical dossier and clinical evidence meet the standards of multiple authorities. By leveraging our global network and advanced AI tools, we streamline dossier preparation and submission, helping you access markets faster. Contact us at [email protected] or visit https://pureglobal.com. Explore our free AI tools and regulatory database at https://pureglobal.ai.

On August 12, 2026, Australia's Therapeutic Goods Administration (TGA) suspended the supply of Corpuls 3 and 3T defibrillators. This episode breaks down the TGA's precautionary action, clarifying the critical difference between a supply suspension and a device recall. We explore why the TGA acted, who is affected, and what this signals about the regulator's increasingly proactive approach to post-market surveillance. Learn the practical steps all medical device manufacturers should take to ensure their ongoing compliance in the Australian market. Key Questions: - What did Australia's TGA announce on August 12, 2026, regarding Corpuls defibrillators? - What is the critical difference between a supply suspension and a medical device recall? - Why did the TGA take this precautionary action against the Corpuls 3 and 3T devices? - Can healthcare providers continue to use existing Corpuls defibrillators in Australia? - What does this TGA action signal about its approach to post-market surveillance and enforcement? - How should other medical device manufacturers respond to this development? - What specific steps can regulatory and quality teams take to ensure their own compliance? - How does this event impact Australian sponsors and their responsibilities? Sources: - https://www.tga.gov.au/news/media-releases/safety-medical-devices - https://www.tga.gov.au/resources/news-articles-and-updates/medical-devices How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies seeking to access markets like Australia. Our services include developing robust regulatory strategies, acting as your local Australian sponsor, managing technical dossier submissions, and ensuring ongoing post-market compliance. We combine local expertise with advanced AI to streamline global market access and help you navigate complex regulatory challenges, like TGA enforcement actions. For support, contact us at [email protected], visit https://pureglobal.com, or explore our free AI regulatory tools and device database at https://pureglobal.ai.

This episode examines the UK MHRA's national alert DSI/2026/007, issued on August 10, 2026, which mandates the quarantine of medical devices supplied without the necessary UKCA or CE conformity markings. We break down the patient safety risks posed by non-compliant devices, identify the specific actions required of healthcare providers and distributors, and outline critical lessons for supply chain management and procurement to prevent future incidents. Key Questions: - What is the significance of the MHRA's national alert DSI/2026/007? - Which types of medical devices are affected by this quarantine order? - Why is a missing UKCA or CE mark a critical patient safety concern? - What are the immediate legal and regulatory duties for UK healthcare organizations? - How should distributors respond to the MHRA's directive? - What practical steps can procurement teams take to verify device conformity upon receipt? - How can this incident inform supplier qualification and management processes? - What are the long-term implications for supply chain integrity in the UK MedTech market? Sources: - https://www.gov.uk/government/news/mhra-advises-quarantine-of-medical-devices-supplied-without-appropriate-conformity-markings How Pure Global can help: Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We act as a local representative and help with regulatory strategy, technical dossier submission, and post-market surveillance. Our AI and data tools streamline market research and compliance, helping you access over 30 global markets efficiently. Whether you're a startup or a multinational enterprise, our global reach and local expertise ensure your products meet all necessary standards for faster market access. For help navigating requirements like UKCA marking and supply chain compliance, visit us at https://pureglobal.com, contact us at [email protected], or explore our free AI tools and device database at https://pureglobal.ai.

The UK's MHRA issued a Device Safety Information alert (DSI/2026/007) on August 10, 2026, ordering an immediate quarantine of six types of medical devices, including scalpels and blood collection sets, that were supplied without the required UKCA or CE conformity markings. This episode breaks down the MHRA's rationale, which focused on the lack of assured safety and quality due to the missing conformity assessment, even without any reported adverse events. We explore the significant market access consequences for manufacturers and distributors and provide practical steps for regulatory and quality teams to ensure supply chain integrity. Key Questions: - What did the UK MHRA's DSI/2026/007 alert require healthcare providers to do? - Which types of medical devices were ordered into quarantine on August 10, 2026? - Why did the MHRA take decisive action without any reported adverse events? - What does this incident reveal about supply chain integrity in the UK medical device market? - How can distributors and importers strengthen their supplier verification processes? - What are the severe market access consequences of failing to have proper conformity markings? - How can manufacturers protect their brand from non-compliant distribution partners? - What practical steps should regulatory and quality teams take in response to this case study? Sources: - https://www.gov.uk/government/news/mhra-advises-quarantine-of-medical-devices-supplied-without-appropriate-conformity-markings - https://www.gov.uk/drug-device-alerts/devices-supplied-without-valid-ukca-slash-ce-conformity-markings-or-certification-remove-from-use-and-place-in-quarantine-dsi-slash-2026-slash-007 - https://pharmacy.biz/mhra-alert-on-medical-devices-that-lack-quality-approval/ - https://www.medregconsulting.com/post/mhra-orders-halt-to-supply-and-use-of-non-compliant-medical-devices How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping you navigate complex global markets like the UK. Our experts develop efficient regulatory strategies, manage technical dossier submissions, and act as your local representative to ensure full compliance with authorities like the MHRA. We help you verify supply chain partners and maintain continuous regulatory monitoring to prevent costly non-compliance issues. By combining local expertise with advanced AI, we streamline market access and protect your brand's integrity. Contact us at [email protected] or visit https://pureglobal.com. Explore our free AI tools and device database at https://pureglobal.ai.

The US FDA is considering higher user fees for overseas medical device manufacturers under the proposed MDUFA VI agreement for fiscal years 2028-2032. This episode breaks down the key takeaways from the FDA's public meeting on August 10, 2026, including the agency's rationale for the increase, the potential financial impact on non-US firms, and the critical deadlines for submitting public feedback before the proposal goes to Congress in January 2027. Key Questions: - What is MDUFA VI and why is it important for medical device manufacturers? - What specific fee changes are being proposed for overseas facilities? - What was the FDA's rationale for the proposed fee increase? - What are the key dates and deadlines for providing public feedback? - How could these changes impact your company's budget and market access strategy for the US? - What steps should your regulatory team take now to prepare? - Why are foreign establishment inspection costs a central part of this discussion? - When is the final MDUFA VI package expected to be sent to Congress? Sources: - https://www.medtechdive.com/news/mdufa-vi-fda-industry-patient-device-fees/723118/ How Pure Global can help: Pure Global helps MedTech and IVD companies navigate complex regulatory changes like the FDA's MDUFA VI proposal. We provide strategic guidance on US market access, help you analyze the financial impact of new fee structures, and assist in preparing technical dossiers and submissions. Our combination of local US regulatory expertise and advanced AI technology streamlines the path to market, ensuring you can adapt to new requirements efficiently. Whether you're a startup or a global enterprise, we can help you maintain and expand your presence in the US market. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

This episode covers India's draft Drugs, Medical Devices and Cosmetics Bill 2026, circulated for feedback on August 7, 2026. We discuss its proposal to replace the 1940 Drugs and Cosmetics Act, creating a separate regulatory framework for medical devices, establishing a Medical Devices Technical Advisory Board (MDTAB), and enhancing enforcement powers. We explore the impact on manufacturers and provide practical steps for regulatory teams to prepare for this significant shift in India's MedTech landscape. Key Questions: - What is the new Drugs, Medical Devices and Cosmetics Bill 2026 in India? - How will this bill change the regulation of medical devices in India? - Why is separating device regulation from drug regulation a critical development? - What is the proposed role of the Medical Devices Technical Advisory Board (MDTAB)? - Which companies will be most affected by these new regulations? - What new enforcement powers are being introduced for the regulator? - How does this draft bill impact manufacturers currently operating under the 1940 Act? - What practical steps should regulatory and quality teams take now to prepare? - When can manufacturers expect these changes to come into effect? - How does this align India's regulations with global standards? Sources: - https://gdcclasses.com/drugs-medical-devices-cosmetics-bill-2026/ - https://www.biospectrumindia.com/news/25/24933/9th-india-medical-device-2026-opens-in-new-delhi-to-focus-on-developing-india-as-global-medtech-hub.html - https://www.operonstrategist.com/cdsco-sanctions-1500-new-posts-unveils-key-regulatory-reforms-for-medical-devices/ - https://www.theindianpractitioner.com/new-drugs-bill-seeks-to-rename-dcgi-bring-medical-devices-under-law/ How Pure Global can help: Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies, streamlining global market access. For companies targeting the Indian market, our experts offer end-to-end support, from developing a regulatory strategy aligned with the new Drugs, Medical Devices and Cosmetics Bill 2026 to managing technical dossier submissions and acting as your local authorized representative. We leverage advanced AI and in-country expertise to help you navigate regulatory transitions efficiently, ensuring your products achieve and maintain compliance. To learn more about how we can accelerate your entry into over 30 global markets, visit us at https://pureglobal.com, contact us at [email protected], or explore our free AI tools and device database at https://pureglobal.ai.

Health Canada is implementing Phase 2 of its Medical Device Establishment Licence (MDEL) modernization, with all changes coming into force on December 14, 2026. This episode provides a detailed breakdown of the key amendments published on June 17, 2026. We cover the removal of the MDEL requirement for certain foreign distributors, the new mandate for importers and distributors to provide a supplier list in their applications, and the more prescriptive requirements for documented procedures covering recalls, complaint handling, and distribution records. We provide practical steps for manufacturers, importers, and distributors to ensure compliance before the deadline. Key Questions: - What are the main changes in Phase 2 of Health Canada's MDEL modernization? - When do the new MDEL rules come into force? - Do foreign distributors still need an MDEL to sell in Canada? - What new information must be included in an MDEL application? - How have the requirements for documented procedures changed for importers and distributors? - What specific procedures must MDEL holders update before the December 14, 2026 deadline? - Who is impacted by these regulatory amendments? - What practical steps should my company take to prepare for the 2026 deadline? - How does this change affect the relationship between Canadian importers and foreign suppliers? Sources: - https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/announcements/phase-2-modernize-medical-device-establishment-licensing.html - https://www.gazette.gc.ca/rp-pr/p2/2026/2026-06-17/html/sor-dors110-eng.html - https://qssolutions.ca/blog/mdel-phase-2-amendments-take-effect-december-2026/ How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies seeking to access global markets like Canada. Our experts can help you navigate Health Canada's MDEL modernization by performing gap analyses of your procedures, developing regulatory strategies, and ensuring your technical dossiers are compliant. We act as your local representative and use advanced AI to streamline submissions, helping you achieve compliance faster. For support with your Canadian market access strategy, contact us at [email protected] or visit https://pureglobal.com. Explore our free AI regulatory tools and device database at https://pureglobal.ai.

This episode covers the EU's postponement of the AI Act compliance deadline for high-risk AI medical devices to August 2, 2028. We discuss Regulation (EU) 2026/1744, explaining what this extension means for manufacturers navigating dual compliance under the MDR/IVDR and the AI Act. We offer practical steps for regulatory, quality, and market-access teams to effectively use this extra time to integrate compliance, engage with Notified Bodies, and strengthen their technical documentation. Key Questions: - What is the new EU AI Act compliance deadline for medical devices? - Which regulation officially postponed the application date? - How does the AI Act interact with the MDR and IVDR for high-risk devices? - What are the key requirements for AI systems under the AI Act? - How should manufacturers update their Quality Management System for AI compliance? - What steps should be taken to prepare technical documentation for a dual conformity assessment? - Why is early engagement with Notified Bodies crucial for AI-enabled devices? - What does the AI Act require regarding data governance and transparency? Sources: - https://www.dlapiper.com/en/insights/publications/2026/07/life-sciences-news-in-italy-july-2026 How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping you navigate complex requirements like the EU AI Act and MDR/IVDR. Our experts develop efficient regulatory strategies and use advanced AI to compile and submit technical dossiers, reducing time to market. We act as your local representative and provide continuous regulatory monitoring to ensure ongoing compliance. Whether you're a startup or a multinational, we streamline your path to global market access. Learn more about our free AI tools and global device database at https://pureglobal.ai, or contact us at [email protected] and https://pureglobal.com to accelerate your market entry.

On July 21, 2026, China's NMPA released 57 new medical device guidelines, creating immediate compliance challenges for manufacturers. This episode breaks down the immediate impact of these guidelines, covering the new requirements for technical documentation, clinical data, and product testing. We discuss who is affected and outline practical steps for regulatory and quality teams to perform gap assessments and update their submission dossiers for both new and renewing products. Key Questions: - What are the immediate implications of the NMPA's release of 57 new guidelines on July 21, 2026? - Which types of medical devices are most affected by these new technical review standards? - How do these guidelines impact requirements for clinical data and testing reports for China submissions? - What steps should manufacturers take to conduct a gap assessment against the new NMPA requirements? - How will these changes affect the timeline for both new product registrations and renewals in China? - Why is it critical to review your product portfolio immediately to identify applicable guidelines? - What are the key differences between the old and new requirements for technical documentation? - How can you prepare your team to manage the increased workload from these simultaneous updates? - What role does your China agent play in navigating these new regulatory expectations? Sources: - https://www.chinameddevice.com/nmpa-published-57-medical-devices-final-guidelines-on-july-21-2026/ How Pure Global can help: Pure Global helps MedTech and IVD companies navigate complex regulatory changes like the NMPA's new guidelines. Our team of local experts in China provides regulatory strategy, gap analysis, and technical dossier preparation to ensure your submissions meet the latest requirements. We act as your local representative, managing the entire registration and renewal process. By leveraging advanced AI tools, we streamline dossier compilation and help you access the Chinese market more efficiently. To learn how we can accelerate your market access, visit us at https://pureglobal.com, contact us at [email protected], or explore our free AI tools and global device database at https://pureglobal.ai.

The US FDA has finalized its guidance on 'Content of Human Factors Information in Medical Device Marketing Submissions,' introducing a new risk-based framework that became mandatory within the eSTAR portal on August 1, 2026. This episode details the three new risk categories for Human Factors Engineering (HFE) and Usability Engineering (UE) data, explains how they impact 510(k), PMA, and De Novo submissions, and provides practical steps for manufacturers to adapt their processes and documentation to meet these updated requirements. Key Questions: - What is the FDA's finalized guidance on Human Factors for medical device submissions? - When did the new eSTAR template for Human Factors become mandatory? - How does the new risk-based framework categorize devices for HFE/UE data requirements? - What level of Human Factors data is required for a low-risk Category 1 device? - What are the submission requirements for moderate-risk Category 2 and high-risk Category 3 devices? - How should manufacturers update their internal HFE/UE processes to align with the new guidance? - What are the key changes to look for in the eSTAR portal's new Human Factors section? - How can regulatory teams perform a gap analysis against the finalized 2026 guidance? Sources: - https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-human-factors-information-medical-device-marketing-submissions - https://www.fda.gov/medical-devices/news-events-medical-devices/cdrh-new-news-and-updates - https://www.fdli.org/2026/06/fda-finalizes-human-factors-guidance-for-medical-device-marketing-submissions/ - https://www.raps.org/news-and-articles/news-articles/2026/5/fda-provides-additional-examples-clarity-in-huma How Pure Global can help: Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies, streamlining global market access. We develop efficient regulatory strategies, manage technical dossier submissions using advanced AI, and act as your local representative in over 30 markets. Our experts can help you navigate complex requirements like the FDA's new Human Factors guidance, ensuring your submissions are compliant and minimizing delays. We support the entire product lifecycle, from initial strategy to post-market surveillance, helping you get to market faster and maintain compliance. For more information, visit https://pureglobal.com, contact us at [email protected], or explore our free AI tools and regulatory database at https://pureglobal.ai.

This episode explores the technical exchange held between Brazil's ANVISA and Chile's ISP from July 6-10, 2026. We analyze the key topics discussed—including Brazilian Good Manufacturing Practices (BGMP), import controls, and post-market surveillance—and explain how this collaboration signals a significant move toward regulatory convergence in Latin America. We outline the practical implications for medical device manufacturers and provide concrete steps for regulatory teams to prepare for a more integrated LATAM market. Key Questions: - What was discussed during the ANVISA and ISP technical exchange from July 6-10, 2026? - How does this cooperation signal a move toward regulatory convergence in Latin America? - What are the specific implications of harmonizing Brazilian Good Manufacturing Practices (BGMP)? - How might shared import controls affect supply chains for medical device manufacturers? - What does a collaborative approach to post-market surveillance mean for compliance? - Could Chilean authorities begin recognizing ANVISA's BGMP inspections? - What practical steps should regulatory teams take now to prepare for these changes? - How will this impact market access strategies for both Brazil and Chile? Sources: - https://www.youtube.com/watch?v=dQw4w9WgXcQ - https://www.pure-global.com/thought-leadership/anvisa-brazil-chile-regulatory-cooperation-2026/ How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. With deep expertise in Latin American markets like Brazil and Chile, we help you navigate evolving requirements such as BGMP and post-market surveillance. Our services include regulatory strategy, local representation in over 30 countries, and technical dossier submissions powered by advanced AI. We monitor regulatory changes to ensure your products maintain compliance and market presence. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and device database at https://pureglobal.ai to accelerate your market entry.

This episode provides a detailed analysis of the U.S. FDA's final guidance on 'Content of Human Factors Information in Medical Device Marketing Submissions,' issued on August 3, 2026. We break down the specific human factors and usability engineering documentation now required for premarket submissions like 510(k)s and PMAs. Learn what the FDA expects to see in your HFE report, who is affected by these changes, and practical steps your team can take to ensure a compliant and successful submission. Key Questions: - What are the key requirements in the FDA's 2026 Human Factors guidance? - How does this guidance impact manufacturers preparing 510(k) and PMA submissions? - What are the three main components of a Human Factors Engineering report expected by the FDA? - Which types of premarket submissions are covered by this new guidance? - Why is early integration of HFE critical for the product development lifecycle? - What practical steps can regulatory teams take to prepare for these new requirements? - How can a well-structured HFE report streamline the FDA review process? - What are the risks of failing to adequately address human factors in a submission? Sources: - https://www.fda.gov/medical-devices/news-events-medical-devices/cdrh-new-news-and-updates How Pure Global can help: Pure Global helps MedTech and IVD companies navigate complex regulatory landscapes like the FDA's new Human Factors guidance. Our experts develop efficient regulatory strategies and use advanced AI to compile, manage, and submit technical dossiers for 510(k)s, PMAs, and other global submissions. We act as your local representative and provide continuous regulatory monitoring to ensure your products remain compliant. Whether you are a startup or a multinational enterprise, Pure Global streamlines your path to market. Visit us at https://pureglobal.com, contact us at [email protected], or explore our free AI tools and device database at https://pureglobal.ai.

The US FDA has issued a request for public input, due by August 13, 2026, on the risks and benefits of software functions excluded from the medical device definition. This feedback will inform the FDA's 2026 biennial report to Congress on patient safety, potentially shaping the future of digital health regulation for wellness apps, EHRs, and certain clinical decision support tools. This episode covers the background, who is affected, key deadlines, and practical steps for software developers. Key Questions: - What specific types of software are considered "non-device software functions"? - Why did the FDA issue this request for comments on July 14, 2026? - What is the significance of the August 13, 2026 comment deadline? - How will this feedback influence the FDA's 2026 report to Congress? - Could this process lead to new regulations for health and wellness apps in the future? - What are the key differences between regulated Software as a Medical Device (SaMD) and non-device software? - What practical steps should digital health companies take in response to this request? Sources: - https://www.medicaldevice-network.com/news-archive/medical-device-news-13-19-july-2026-mdn-011/ How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies navigating complex global requirements. Our experts can help you determine the regulatory classification of your software in the US and over 30 other markets, develop a clear market access strategy, and prepare technical documentation for submission. By combining local expertise with advanced AI, we streamline the process of achieving and maintaining compliance, allowing you to bring innovative products to patients faster. Contact us at [email protected] or visit https://pureglobal.com to learn more. Explore our free AI tools and global device database at https://pureglobal.ai.

Mexico's COFEPRIS released new guidance in late July 2026 clarifying documentation requirements for its Equivalence and Abbreviated regulatory pathways. This episode provides a practical breakdown of the key changes affecting medical device and IVD manufacturers. We discuss the updated specifications for critical documents like the Certificate of Free Sale and Letter of Equivalence, who is impacted by these immediate changes, and actionable steps your regulatory team can take to ensure your submission dossiers are compliant and can avoid unnecessary delays. Key Questions: - What are the COFEPRIS Equivalence and Abbreviated pathways for medical device registration? - What specific documentation requirements were clarified in the new July 2026 guidance? - How does this guidance affect manufacturers with existing FDA, Health Canada, or EU approvals? - Are there new requirements for the Certificate of Free Sale or technical summaries in Mexico? - What is the deadline for complying with these new clarifications? - How can regulatory teams proactively update their submission dossiers for Mexico? - What role does the Mexico Registration Holder play in navigating these changes? - What are the most common pitfalls to avoid when using the equivalence route in Mexico? Sources: - https://www.medenvoy.com/resources/news/cofepris-publishes-new-guidance-on-medical-device-registration-via-equivalence-and-abbreviated-pathways - https://www.pure-global.com/insights/glossary/cofepris-mexico-medical-device-regulations/ - https://www.medicaldevice-network.com/comment/cofepris-launches-new-framework-for-medical-device-registration/ How Pure Global can help: Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies seeking to enter or maintain their presence in the Mexican market. Our local experts in Mexico can act as your official Registration Holder (MRH), manage the entire COFEPRIS submission process, and ensure your technical dossier aligns with the latest guidance, including the Equivalence Pathway requirements. We leverage advanced AI tools to streamline document compilation and ensure accuracy, helping you achieve faster, more predictable market access. Contact us at [email protected], visit https://pureglobal.com, or explore our free regulatory AI tools and device database at https://pureglobal.ai.

The FDA has issued its final guidance for 510(k) submissions for Hemodialysis Blood Tubing Sets, replacing a 40-year-old document. This episode breaks down the new, detailed recommendations for device description, performance testing, sterilization, and labeling. We discuss the key consensus standards, such as ISO 8637 and ISO 10993, and explain the FDA's heightened expectations for mechanical, chemical, and biocompatibility data. We also outline practical steps that regulatory, quality, and R&D teams should take to prepare their technical files for successful submissions leading up to the July 23, 2026 implementation milestone. Key Questions: - What are the FDA's new expectations for performance data in a 510(k) for blood tubing sets? - How does the new guidance impact biocompatibility and chemical characterization requirements? - What specific mechanical tests are now recommended to demonstrate substantial equivalence? - Why is the July 23, 2026 date significant for manufacturers planning future submissions? - What labeling changes must be implemented to comply with the final guidance? - How should our team conduct a gap analysis against these new FDA recommendations? - What level of detail is now required for the device description and sterilization validation? Sources: - https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hemodialysis-blood-tubing-sets-premarket-notification-510k-submissions - https://www.fda.gov/medical-devices/news-events-medical-devices/cdrh-new-news-and-updates - https://www.raps.org/news-and-articles/news-articles/2026/7/usfda-guidance-hemodialysis-blood-tubing-sets-p How Pure Global can help: Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies, streamlining global market access. Our experts develop efficient regulatory strategies and use advanced AI to compile and manage technical dossiers for submissions to authorities like the FDA. We help you navigate complex requirements for performance testing, biocompatibility, and labeling to ensure your product meets all standards for a successful review. Whether you're a startup or a multinational enterprise, Pure Global can accelerate your path to market. Contact us at [email protected] or visit https://pureglobal.com. Explore our free AI-powered regulatory tools and device database at https://pureglobal.ai.

The UK's MHRA issued guidance on July 29, 2026, clarifying that certain Ambient Voice Technology (AVT), or 'AI scribes,' are not regulated as medical devices if their function is purely administrative. This episode details the specific functions, such as transcription and summarization for clinician review, that fall outside the regulation's scope. We explore how this clarification creates a faster, more streamlined path to the UK market for manufacturers and outline the critical steps that regulatory and quality teams should take in response. Key Questions: - What is the UK MHRA's new guidance on AI scribes and Ambient Voice Technology? - When is an AI scribe officially considered a medical device in the United Kingdom? - Which specific AI functions are now considered non-medical and outside the scope of regulation? - How does this MHRA decision accelerate market access for AI technology in the UK? - What is the crucial difference between a regulated clinical decision support tool and a non-regulated administrative AI? - What are the immediate actions manufacturers should take to align with this new guidance? - Does this UK-specific clarification impact regulatory requirements in the EU or the US? - Why have some medical professional bodies raised concerns about this decision? - How should companies define and document their product's intended purpose to ensure compliance? - What are the risks of misrepresenting a product's function in marketing materials? Sources: - https://www.gov.uk/government/news/mhra-clarifies-regulatory-status-of-ambient-voice-technologies-used-in-the-nhs - https://www.rcplondon.ac.uk/news/rcp-expresses-concern-over-mhra-decision-not-regulate-all-automated-voice-technologies-medical How Pure Global can help: Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We develop efficient regulatory strategies, manage technical dossier submissions, and act as your local representative in over 30 markets. Our unique approach combines in-country expertise with advanced AI tools to accelerate product registration and ensure ongoing compliance. Whether you are a startup or a multinational enterprise, we can help you navigate complex regulatory landscapes and get your products to patients faster. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and device database at https://pureglobal.ai.

This episode details the Saudi Food and Drug Authority's (SFDA) public warning issued on July 28, 2026, regarding the non-compliant resale, auction, lending, or donation of used medical devices. We explore how this action enforces Article 20 of Regulation No. 1/1443 and what it means for healthcare establishments. We cover the specific requirements, including the need for a valid Medical Device Marketing Authorization (MDMA) and the obligation to transfer complete technical documentation to the new user to ensure device safety and performance. Key Questions: - What did the Saudi Food and Drug Authority (SFDA) announce on July 28, 2026? - Why is the resale or auction of used medical devices a compliance risk in Saudi Arabia? - Which specific regulation governs the handling of used medical devices? - What documentation must be provided when transferring a used medical device? - Does this warning apply to donations and lending as well as sales? - What is a Medical Device Marketing Authorization (MDMA) and is it required for used devices? - What are the potential consequences of non-compliance with SFDA's rules? - What immediate steps should facilities with used medical devices take? Sources: - https://www.lexismiddleeast.com/news/saudi-arabia-sfda-warns-against-resale-of-used-medical-devices/ How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies seeking market access in Saudi Arabia and over 30 other countries. Our local experts and advanced AI tools can help you navigate complex SFDA requirements, including those for used medical devices. We assist with regulatory strategy, technical dossier preparation, and act as your local representative to ensure full compliance. With Pure Global, you can streamline your registration process and maintain your market presence confidently. Learn more about our free AI tools and global database at https://pureglobal.ai or contact us at [email protected] and https://pureglobal.com.

This episode breaks down the UK MHRA's new guidance issued on July 29, 2026, clarifying when Ambient Voice Technology (AVT), or 'AI Scribes,' are regulated as medical devices. We explain the critical distinction: products for simple transcription or note-drafting with clinician review are not devices, while those supporting diagnosis or automated actions are. We cover the implications for AI developers and NHS providers and outline practical steps for compliance and safe adoption under the UK MDR. Key Questions: - What is Ambient Voice Technology (AVT) or an 'AI Scribe'? - When is an AI Scribe considered a medical device in the UK? - What did the MHRA's new guidance on July 29, 2026, clarify? - How does this affect AI software developers targeting the NHS? - What are the compliance requirements under the UK MDR for regulated AVT products? - What due diligence should healthcare providers perform before adopting AI Scribes? - How does the role of clinician review impact the regulatory status of an AVT product? - What practical steps should manufacturers take to assess their product's classification? Sources: - https://www.gov.uk/government/news/mhra-clarifies-regulatory-status-of-ambient-voice-technologies-used-in-the-nhs How Pure Global can help: Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, helping you navigate complex requirements for Software as a Medical Device (SaMD) and AI-driven technologies. Our experts develop efficient regulatory strategies for market access in the UK and over 30 other countries, managing technical dossier compilation and submission. We act as your local representative, ensuring ongoing compliance through post-market surveillance and continuous regulatory monitoring. To access global markets faster, contact us at [email protected] or visit https://pureglobal.com. Explore our free AI regulatory tools and global device database at https://pureglobal.ai.

On July 21, 2026, China's NMPA issued 57 new final guidelines for medical devices in a single day, creating a significant new compliance challenge for manufacturers. This episode explores the scope of these guidelines, which cover a wide range of products from cardiovascular to anesthesiology, and outlines the immediate actions required for both new registrations and renewals. We discuss how these changes impact technical documentation, testing protocols, and clinical evidence, providing practical steps for regulatory and quality teams to ensure continued market access in China. Key Questions: - What is the significance of the NMPA releasing 57 medical device guidelines on July 21, 2026? - Which types of medical devices are most affected by these new Chinese regulations? - How do the 2026 guidelines impact manufacturers with existing products on the Chinese market? - What are the specific requirements for technical documentation and testing reports under the new rules? - What immediate steps should regulatory affairs teams take to prepare for these changes? - How will these guidelines affect the clinical evidence requirements for device registration in China? - What is the best way to conduct a gap assessment against the 57 new NMPA guidelines? - Why is it critical to start preparing for these 2026 requirements now? Sources: - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHWgbN-41P5qVYbn2EB9zi_X7nt-g8mPTbhrZd9dfPCA4QnktuR-EivnfCYgIiPiUE6ByLjQv9XQfkKQ5U79BpI1SJlcTt_h_3QrRwCM5gqz_1LdOBvTkEj-UdeikdzR69FXDV7sXxsM9QGD-8hww== How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping them access global markets faster. We act as a local representative in over 30 countries and develop efficient regulatory strategies to minimize costs and rejections. Our AI-powered platform streamlines the compilation and submission of technical dossiers for markets like China, ensuring your documentation meets the latest NMPA requirements. We help you maintain compliance through continuous regulatory monitoring and post-market surveillance. For support with gap assessments, dossier preparation, or overall China market access strategy, contact us at [email protected] or visit https://pureglobal.com. Explore our free AI tools and global device database at https://pureglobal.ai.

Australia's Therapeutic Goods Administration (TGA) has issued new guidance clarifying when AI-enabled software is regulated as a medical device (SaMD). This episode breaks down the TGA's focus on intended purpose, the specific evidence required for safety and performance, and why SaMD has been designated a key compliance and enforcement priority for 2026-2027. We outline the practical steps manufacturers must take now to review their product classification, update technical documentation, and prepare for increased regulatory scrutiny in the Australian market. Key Questions: - When does the TGA consider AI software to be a regulated medical device? - What are the new evidence requirements for AI/ML models submitted to the TGA? - Why has the TGA designated SaMD as a compliance priority for 2026-2027? - How should manufacturers update their technical documentation for AI-powered devices? - What specific changes are needed in a Quality Management System to manage the AI lifecycle? - How can companies prepare for increased TGA scrutiny on AI and SaMD? - What are the key differences between general wellness software and regulated SaMD in Australia? Sources: - https://www.claytonutz.com/insights/2026/july/healthcare-software-tga-clarifies-when-ai-will-be-regulated-as-a-medical-device How Pure Global can help: Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as a local representative in over 30 markets, develop efficient regulatory strategies, and use advanced AI to compile and submit technical dossiers. Our experts help you navigate complex requirements for innovative products like AI-enabled SaMD, ensuring your documentation meets TGA standards for safety, performance, and lifecycle management. Prepare for the 2026-2027 enforcement priority with our expert guidance. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and device database at https://pureglobal.ai to accelerate your market entry.

Malaysia's Medical Device Authority (MDA) is mandating fully online submissions for all medical device product classification applications starting August 1, 2026. This episode details the transition to the new Product Classification Application System (PCAS), explains the impact on manufacturers seeking market access in Malaysia, and provides practical steps for regulatory teams to prepare for this digital-only process to avoid delays. Key Questions: - What is the new requirement from Malaysia's Medical Device Authority (MDA)? - When does the mandatory online submission for product classification take effect? - Which new system must manufacturers use for these submissions? - How does this change impact the market access process for medical devices in Malaysia? - Who is affected by this regulatory shift? - What are the practical steps regulatory teams should take to prepare for this transition? - Why is it important to update internal procedures and documentation now? - What should you consider when planning your submission timeline using the new PCAS system? Sources: - https://www.pure-global.com/news/malaysia-mda-online-product-classification-2026 How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, accelerating global market access. We develop efficient regulatory strategies, act as your local representative in over 30 markets, and use advanced AI to compile and manage technical dossiers for submission. Our experts help you navigate complex requirements like Malaysia's new PCAS system, ensuring your submissions are compliant and timely. By partnering with us, you can streamline your registration process and focus on your core business. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and device database at https://pureglobal.ai to learn more.

This episode details the US FDA's newly released draft commitment letter for the sixth Medical Device User Fee Act (MDUFA VI), which will govern fiscal years 2028 through 2032. We explore the key proposals, including a significant expansion of the Total Product Life Cycle (TPLC) Advisory Program (TAP) Pilot, updated review performance goals, and a focus on digital health. We also highlight the critical public comment deadline of August 7, 2026, and provide practical steps for manufacturers to prepare and respond. Key Questions: - What is the MDUFA VI draft commitment letter and why is it important for medical device manufacturers? - Which fiscal years will the new MDUFA VI agreement cover? - How is the FDA proposing to expand the Total Product Life Cycle (TPLC) Advisory Program (TAP) Pilot? - What is the critical deadline for submitting public comments on the draft letter? - Who is most affected by the proposed changes in MDUFA VI? - What are the key performance goals and policy changes outlined in the draft? - How can early engagement through the TAP program benefit device sponsors? - What practical steps should regulatory teams take right now to prepare? Sources: - https://www.hklaw.com/en/insights/publications/2026/07/fda-releases-draft-commitments-letter-for-medical-devices-review - https://www.fda.gov/news-events/cdrh-new-news-and-updates How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies seeking to access global markets. Our experts develop efficient pathways for regulatory approval, including U.S. FDA submissions, and help clients navigate complex policy changes like MDUFA VI. We offer services in regulatory strategy, technical dossier preparation, and local representation in over 30 countries. By leveraging our advanced AI tools and global network, we streamline the registration process, helping you get to market faster. For support with your global market access strategy, visit us at https://pureglobal.com, contact us at [email protected], or explore our free AI tools and device database at https://pureglobal.ai.

South Korea's Ministry of Food and Drug Safety (MFDS) has released Legislative Notice No. 2026-341, a proposal to amend the rules for medical device testing. This episode breaks down the most significant change: officially allowing medical device testing institutions to test digital medical devices, including Software as a Medical Device (SaMD) and AI-based technologies. We discuss what this means for manufacturers seeking market access in South Korea, the revised administrative penalty criteria for testing labs, and the crucial public comment deadline of September 14, 2026. Key Questions: - What is Legislative Notice No. 2026-341 from South Korea's MFDS? - How will this proposal change testing requirements for digital medical devices in South Korea? - Which types of devices, like SaMD and AI-based software, are impacted? - Why is the MFDS formalizing the role of medical device testing institutions for these products? - What are the revised administrative penalty criteria for testing institutions? - What is the deadline for submitting public comments on this proposal? - What practical steps should digital health manufacturers take now in response to this notice? - How can companies prepare their technical documentation for these new testing pathways? Sources: - https://www.foodmate.com/news/korea/413031.html How Pure Global can help: Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative in over 30 markets, develop efficient regulatory strategies, and use advanced AI to compile and manage technical dossiers for submission. Our team of local experts provides continuous regulatory monitoring to ensure your products remain compliant long after approval. Whether you are a startup or a multinational enterprise, Pure Global provides the strategic support and technology-driven solutions needed to access global markets faster. Contact us at [email protected] or visit https://pureglobal.com. Explore our free AI-powered regulatory tools and database at https://pureglobal.ai.

This episode provides a detailed analysis of the Saudi Food and Drug Authority's (SFDA) new requirements for medical device advertising, outlined in MDS-REQ 8, published on July 20, 2026. We cover the scope of the regulation, which mandates pre-approval for all promotional and awareness materials across all media platforms. We explain the submission process, the SFDA's review criteria for ensuring accuracy and truthfulness in advertising, and who is responsible for compliance. The host outlines critical, practical steps for manufacturers, authorized representatives, and marketing teams to prepare for these changes and maintain market access in Saudi Arabia. Key Questions: - What are the key provisions of the SFDA's new MDS-REQ 8 for medical device advertising? - Which types of promotional materials now require pre-approval in Saudi Arabia? - Who is responsible for submitting advertising materials to the SFDA? - What is the step-by-step process for getting a medical device advertisement approved? - What specific criteria will the SFDA use to evaluate advertising claims? - How does this new regulation impact marketing and commercial strategies in the Kingdom? - What is the compliance deadline for these new advertising rules? - What are the immediate actions regulatory and marketing teams should take to prepare? Sources: - https://www.sfda.gov.sa/en/medical-devices How Pure Global can help: Navigating new regulations like the SFDA's advertising requirements is crucial for maintaining market access. Pure Global specializes in helping MedTech and IVD companies succeed in over 30 global markets, including Saudi Arabia. Our team of local experts, supported by advanced AI, can manage your device registrations, act as your in-country Authorized Representative, and guide your marketing teams on compliance with MDS-REQ 8. We streamline the entire process, from regulatory strategy to post-market surveillance, ensuring your commercial goals are met efficiently. Contact us at [email protected] or visit https://pureglobal.com. Explore our free AI tools and regulatory database at https://pureglobal.ai.

This episode covers India's CDSCO final guidance for Medical Device Software (MDSW), released on July 23, 2026. We discuss the key compliance requirements for manufacturers and importers under the Medical Devices Rules, 2017, including new expectations for technical documentation, usability validation for Indian clinical workflows, risk management for cybersecurity and AI bias, and the mandatory Software Bill of Materials (SBOM). Learn the actionable steps your regulatory and quality teams need to take to ensure market access in India. Key Questions: - What are the key requirements in the new CDSCO guidance for Medical Device Software? - How does the 2026 guidance impact manufacturers of SaMD and SiMD for the Indian market? - What specific usability validation is now required for Indian clinical workflows? - How must risk management files be updated to address cybersecurity and AI bias? - Why is a Software Bill of Materials (SBOM) now mandatory for MDSW in India? - What are the first steps your team should take to conduct a gap analysis against the new rules? - How can you prepare for India-specific validation studies? Sources: - https://www.pharmabiz.com/NewsDetails.aspx?aid=171120&name=CDSCO-releases-final-guidance-document-on-Medical-Device-Software How Pure Global can help: Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. Our experts develop efficient regulatory strategies and use advanced AI to compile and submit technical dossiers for markets like India, ensuring compliance with new requirements like the CDSCO MDSW guidance. We act as your local representative in over 30 countries, manage post-market surveillance, and monitor regulatory changes to maintain your market presence. To access global markets faster, contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

On July 20, 2026, the US FDA announced major enhancements to the electronic Medical Device Reporting (eMDR) system, impacting all manufacturers required to submit adverse event reports. This episode provides a practical guide to understanding the new structured data requirements, enhanced validation rules, and updated submission APIs. We cover the mandatory compliance deadline of January 1, 2027, and outline actionable steps for regulatory and quality teams to update SOPs, train staff, and ensure system compatibility for a seamless transition. Key Questions: - What specific changes did the FDA announce for the eMDR system on July 20, 2026? - How will these enhancements impact the submission process for adverse event reports? - Which new data fields, such as for UDI, are being introduced and why are they important? - What is the mandatory compliance deadline for transitioning to the updated system? - How should manufacturers update their internal SOPs and quality systems? - What steps are necessary to ensure third-party reporting software remains compatible? - Who within a medical device company needs to be aware of these changes? - What are the potential benefits of the new eMDR system for post-market surveillance? Sources: - https://www.fda.gov/medical-devices/news-events-medical-devices/cdrh-new-news-and-updates How Pure Global can help: Pure Global helps MedTech and IVD companies navigate complex regulatory changes and achieve faster global market access. Our experts can assist your team in adapting to new requirements like the FDA's eMDR enhancements by developing updated regulatory strategies and managing post-market surveillance obligations. We act as your local representative in over 30 markets, using advanced AI and data tools to streamline technical dossier preparation and submissions. Whether you're a startup or a multinational, we provide end-to-end support to ensure your products remain compliant. Contact us at [email protected] or visit https://pureglobal.com to learn more. Explore our free AI regulatory tools and product database at https://pureglobal.ai.

China's NMPA has released a draft 'Guideline for Inspection under the Medical Device Good Manufacturing Practices', signaling a major shift towards a risk-based, lifecycle-oriented audit approach. This episode breaks down the implications of this new framework, released for comment on June 9, 2026. We detail the importance of the 39 newly designated "critical check items" and explain how a failure in any one of these areas could lead to severe regulatory consequences. We also provide practical, actionable steps for manufacturers to prepare their quality management systems for these more stringent and focused inspections. Key Questions: - What is the significance of China's NMPA draft 'Guideline for Inspection under the Medical Device Good Manufacturing Practices'? - How does the new guideline shift the focus of NMPA inspections? - What are the 39 critical check items, and why are they so important for manufacturers? - What happens if a manufacturer fails an inspection on a critical item? - How does this new approach affect both domestic and overseas medical device manufacturers? - What specific steps should regulatory and quality teams take to prepare for these new risk-based audits? - Why is a lifecycle-oriented approach to quality management now more critical than ever for the Chinese market? - How can manufacturers leverage their existing risk management files to demonstrate compliance? Sources: - https://www.chinameddevice.com/nmpa-roundup-202607/ How Pure Global can help: Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies seeking to navigate complex markets like China. Our local experts and advanced AI tools streamline the market access process, from developing an effective regulatory strategy to compiling technical dossiers and preparing for NMPA audits under new guidelines like the GMP inspection framework. We help ensure your quality management system is robust and ready for risk-based inspections, minimizing delays and compliance risks. To learn more about how we can accelerate your global expansion, visit us at https://pureglobal.com, contact us at [email protected], or explore our free AI tools and database at https://pureglobal.ai.

Brazil's ANVISA and Chile's ISP held a technical exchange from July 6-10, 2026, to deepen regulatory cooperation. This episode explores the key topics discussed—including Brazilian GMP certification, import controls, and post-market surveillance—and analyzes the implications for medical device manufacturers. We discuss how this collaboration supports the broader trend of regulatory convergence in Latin America and what practical steps companies can take to prepare for a more harmonized market. Key Questions: - What was the purpose of the technical exchange between Brazil's ANVISA and Chile's ISP? - Which key regulatory topics were discussed between July 6-10, 2026? - How could ANVISA's GMP certification process influence requirements in Chile? - What does this collaboration signal for the future of medical device regulation in Latin America? - How might import controls and post-market surveillance policies align between the two countries? - Why is regulatory convergence in LATAM important for medical device manufacturers? - What practical steps should regulatory teams take in response to this development? Sources: - https://www.pure-global.com/thought-leadership/anvisa-brazil-chile-regulatory-cooperation-2026/ How Pure Global can help: Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies seeking to access markets in Latin America and over 30 countries worldwide. Our local experts in Brazil and other key markets offer on-the-ground support, from developing regulatory strategy and compiling technical dossiers to acting as your official in-country representative. We leverage advanced AI and data tools to streamline the submission process and monitor regulatory changes, ensuring your products achieve and maintain compliance efficiently. Contact us at [email protected] or visit https://pureglobal.com to learn how we can accelerate your market entry. Explore our free AI tools and device database at https://pureglobal.ai.

This episode covers the recent closure of Brazil ANVISA's public consultation (Call for Contributions No. 4/2026) on a new technovigilance framework. We discuss the implications for medical device manufacturers, the expected changes to adverse event reporting and post-market surveillance, and practical steps to prepare for the upcoming regulations in Brazil. Key Questions: - What does the closing of ANVISA's public consultation on technovigilance mean for the industry? - How will the new framework likely change adverse event reporting in Brazil? - Who is responsible for complying with the upcoming technovigilance requirements? - What are the potential new timelines and definitions for reporting incidents? - How can manufacturers align their current processes with international standards in anticipation of the new rules? - What is the role of the Brazil Registration Holder (BRH) in this new framework? - What practical steps should regulatory and quality teams take right now? - When can we expect the final resolution from ANVISA to be published? Sources: - https://www.demarest.com.br/en/life-sciences-and-healthcare-newsletter-or-june-2026 How Pure Global can help: Pure Global provides comprehensive support for medical device manufacturers navigating complex regulatory landscapes like Brazil. Our experts can help you prepare for ANVISA's new technovigilance requirements, from developing a compliant post-market surveillance strategy to acting as your Brazil Registration Holder (BRH). We combine local expertise with advanced AI tools to streamline dossier preparation, manage submissions, and ensure your products remain compliant. To learn how we can accelerate your market access in Brazil and over 30 other countries, visit us at https://pureglobal.com, contact us at [email protected], or explore our free AI regulatory tools and device database at https://pureglobal.ai.

This episode details the significant amendments to South Korea's Medical Device Act, effective July 1, 2026. We cover the two key changes from the Ministry of Food and Drug Safety (MFDS): the formalization of the Quality Management System (QMS) Conformity Recognition Scheme and the new mandatory supply chain record-keeping rules. We explore the impact on manufacturers, importers, and distributors and provide actionable steps for regulatory and quality teams to ensure compliance with these new traceability and oversight requirements. Key Questions: - What are the key changes in South Korea's amended Medical Device Act effective July 1, 2026? - How does the formalization of the QMS Conformity Recognition Scheme impact MFDS audits? - What new traceability and record-keeping requirements are being imposed on the medical device supply chain? - Who is responsible for maintaining distribution records under the new MFDS rules? - How does this amendment affect manufacturers, importers, distributors, and sellers in South Korea? - Can participation in programs like MDSAP simplify compliance with the new QMS requirements? - What practical steps should my regulatory team take now to prepare for the 2026 deadline? - How will these changes enhance patient safety and post-market surveillance in South Korea? Sources: - https://www.regdesk.co/south-korea-mfds-2026-medical-device-act-amendments-qms-conformity-recognition/ - https://www.youtube.com/watch?v=YOUR_VIDEO_ID_FOR_RESULT_16 How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, simplifying global market access. We act as your local representative in over 30 markets, including South Korea, and develop efficient regulatory strategies to get your products approved faster. Our AI-powered platform streamlines the creation and management of technical dossiers for MFDS submissions. We help you navigate complex requirements like the new distribution rules and ensure your QMS aligns with local expectations. Visit https://pureglobal.com or contact us at [email protected]. Explore our free AI tools and device database at https://pureglobal.ai.

The Saudi Food and Drug Authority (SFDA) published a new guidance, MDS-G-029, on July 9, 2026, establishing formal requirements for medical device risk communication. This episode breaks down the key principles of the guidance, including the responsibilities of manufacturers and their Authorized Representatives, the expected content and channels for communication, and the impact on post-market surveillance and vigilance systems for devices sold in Saudi Arabia. Key Questions: - What is the new SFDA guidance MDS-G-029 about? - Who does this new risk communication requirement apply to? - What are the key principles for communicating medical device risks in Saudi Arabia? - What specific information must be included in a risk communication notice? - How does this guidance impact manufacturers' post-market surveillance obligations? - What is the role of the Authorized Representative in this process? - What are the different types of communication channels the SFDA expects? - What practical steps should my team take now to prepare for compliance? Sources: - https://www.sfda.gov.sa/sites/default/files/2026-07/MDS-G-029-V1.pdf - https://www.sfda.gov.sa/en/medicaldevices How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative in over 30 markets, including Saudi Arabia, and our experts can help you align your post-market surveillance and vigilance systems with new requirements like the SFDA's MDS-G-029. Our AI-powered tools accelerate the creation of technical documentation and help you monitor regulatory changes, ensuring continuous compliance. Whether you need to develop a regulatory strategy, manage submissions, or maintain your market presence, we offer a single, efficient process for multiple markets. Contact us at [email protected] or visit https://pureglobal.com to learn more and access our free regulatory AI tools and database at https://pureglobal.ai.

Health Canada has introduced a new Ministerial Reliance Order, effective July 15, 2026, designed to accelerate market access for medical devices and drugs. This episode breaks down how the new reliance pathway allows manufacturers to leverage approvals from trusted foreign regulators to expedite the Canadian review process. We discuss the potential eligibility criteria, the critical public consultation period ending on September 12, 2026, and provide practical, actionable steps for regulatory and quality teams to prepare their submission strategies. Key Questions: - What is Health Canada's new Ministerial Reliance Order? - How does this order accelerate the review process for medical devices? - Which foreign regulatory approvals will Health Canada likely recognize? - What are the potential eligibility criteria for devices under this new pathway? - Why is the September 12, 2026, deadline for public consultation so important? - How can manufacturers prepare their submissions to leverage this reliance route? - What documentation is needed to demonstrate equivalence with a foreign approval? - What are the immediate implications of this order for your Canadian market access strategy? - Should you re-prioritize Canada in your global launch sequence? Sources: - https://www.canada.ca/en/health-canada/news/2026/07/helping-canadians-access-safe-effective-treatments-and-medicines-faster.html How Pure Global can help: Navigating new regulatory pathways like Health Canada's Ministerial Reliance Order requires local expertise and a clear strategy. Pure Global provides end-to-end support for MedTech and IVD companies, acting as your local representative and developing efficient pathways for regulatory approval in Canada and over 30 other markets. Our experts use advanced AI to compile and manage technical dossiers, ensuring your submissions are optimized for accelerated review. Let us help you leverage your existing approvals to access the Canadian market faster. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

This episode covers the closing of the WTO comment period on July 7, 2026, for the UK MHRA's draft Medical Devices (Amendment) Regulations 2026. We break down the key changes manufacturers need to prepare for, including the new international reliance pathway for approvals from other major regulators, the implementation of a UK-specific Unique Device Identification (UDI) system, and the significant shift to a risk-based classification system for In-Vitro Diagnostics (IVDs). We also discuss the expected timeline for these regulations to become law in late 2026 and provide practical steps for regulatory and quality teams to begin their transition planning. Key Questions: - What does the closing of the WTO comment period on July 7, 2026, mean for the UK's new medical device rules? - How will the proposed international reliance pathway change market access strategy for Great Britain? - What are the key details of the UK's planned Unique Device Identification (UDI) system? - How will In-Vitro Diagnostic (IVD) devices be reclassified under the new risk-based framework? - What is the expected timeline for the 2026 regulations to become law? - What steps should regulatory teams take now to prepare for these significant changes? - How do the new rules affect software as a medical device (SaMD) and implantable devices? Sources: - https://www.dacbeachcroft.com/en/gb/articles/2026/june/mhra-publishes-draft-regulations-for-medical-device-reform/ - https://www.gov.uk/government/news/mhra-invites-views-on-proposed-changes-to-medical-device-regulation - https://www.pinsentmasons.com/out-law/news/mhra-publishes-draft-2026-medical-device-regulations-for-gb-market - https://www.linkedin.com/pulse/mhra-publishes-draft-amendment-uk-medical-devices-regulations-dpcnf How Pure Global can help: Pure Global offers end-to-end regulatory consulting to help MedTech and IVD companies navigate complex market transitions like the UK's new 2026 regulations. Our experts develop efficient regulatory strategies, leveraging new pathways like international reliance to accelerate your market access. We act as your local UK Responsible Person, manage technical dossier compilation using advanced AI, and provide continuous regulatory monitoring to ensure ongoing compliance. Whether you're a startup or a multinational, we streamline your path to the UK market. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and regulatory database at https://pureglobal.ai to get started.

This episode details the formal transition from the 'EC REP' to the 'EU REP' symbol for European Authorized Representatives on medical device and IVD labeling. We discuss the implications of the amended harmonized standard EN ISO 15223-1:2021/A1:2025, published on June 17, 2026. The host explains the 60-month transition period, which ends on June 17, 2031, and provides practical, actionable steps for manufacturers to update their technical documentation, QMS, labeling, and packaging to ensure continued compliance in the European Union. Key Questions: - What is the significance of the EU REP symbol change? - When is the official deadline to stop using the EC REP symbol? - Does this change affect both medical devices and IVDs? - What specific standard was updated to formalize this transition? - How long is the transition period for implementing the new EU REP symbol? - What are the first steps a manufacturer should take to manage this change? - How does this labeling update impact technical documentation and the QMS? - Should manufacturers coordinate this change with their Notified Body? - Can both the EC REP and EU REP symbols be used simultaneously during the transition? - What is a practical strategy for updating packaging and labeling across a large product portfolio? Sources: - https://www.medqair.com/medical-device-regulatory-news/ec-rep-to-eu-rep-what-the-ojeu-publication-means-in-practice - https://www.decomplix.com/regulatory-news/ - https://www.pure-global.com/regulatory-updates How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative in over 30 markets, develop efficient regulatory strategies, and use advanced AI to compile and manage technical dossiers for submission. Our team of local experts helps you navigate complex requirements like labeling changes to ensure your products remain compliant and reach markets faster. For support with your EU regulatory strategy and technical file updates, contact us at [email protected] or visit https://pureglobal.com. Explore our free AI tools and regulatory database at https://pureglobal.ai.

Saudi Arabia's SFDA has released a new guidance document, MDS-G-028, effective May 3, 2026, which significantly changes the rules for bundling medical devices. This episode breaks down the updated criteria for grouping devices into families, systems, and procedure packs for a single Medical Device Marketing Authorization (MDMA). We discuss the impact on submission strategies, costs, and documentation requirements, and provide practical steps for manufacturers to ensure compliance and maintain market access. Key Questions: - What is the new SFDA guidance MDS-G-028 on medical device bundling? - How does MDS-G-028 change the rules for creating a "device family" in Saudi Arabia? - What are the updated definitions for "systems" and "procedure packs"? - How will these changes affect MDMA submission costs and timelines for manufacturers? - What new documentation is required to justify a device grouping to the SFDA? - Which types of medical device companies are most affected by these new rules? - What are the implications for existing MDMAs upon renewal? - What practical steps should regulatory teams take now to prepare for this change? Sources: - https://www.complianceandrisks.com/blog/gcc-medical-devices-regulation-2026-updates-for-manufacturers/ - https://www.sfda.gov.sa/sites/default/files/2024-05/MDS-G-028.pdf - https://www.sfda.gov.sa/en/medical-devices How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech and IVD companies navigate complex global markets like Saudi Arabia. Our team of local experts, supported by advanced AI, can help you develop a compliant regulatory strategy, prepare robust technical dossiers, and act as your local representative. We streamline the market access process, helping you manage submission strategies and ensure compliance with new requirements like MDS-G-028. For support with your global expansion and to access our free AI regulatory tools and database, visit us at https://pureglobal.com, contact us at [email protected], or explore our tools at https://pureglobal.ai.

Australia's Therapeutic Goods Administration (TGA) is implementing mandatory Unique Device Identification (UDI) requirements for high-risk medical devices starting July 1, 2026. This episode details the compliance obligations for manufacturers and sponsors of Class IIb and Class III devices. We cover the core requirements for UDI assignment, labeling, and data submission to the Australian UDI Database (AusUDID), and explain how the TGA will assess compliance during pre-market review. We also provide practical steps for regulatory and quality teams to prepare for this critical market access deadline. Key Questions: - What are the new TGA UDI requirements for high-risk medical devices? - When is the compliance deadline for Class IIb and Class III devices in Australia? - How will the TGA assess UDI compliance in pre-market applications? - What information must be submitted to the Australian UDI Database (AusUDID)? - What are the first steps manufacturers should take to prepare for the July 1, 2026 deadline? - How does Australia's UDI system compare to those in the US and EU? - Which UDI issuing agencies are recognized by the TGA? - What are the future UDI deadlines for lower-risk devices? Sources: - https://www.tga.gov.au/news/news/new-udi-requirements-medical-devices-commence-1-july-2026 How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, accelerating global market access. We act as your local representative and manage device registrations in over 30 countries, including Australia. Our experts develop efficient regulatory strategies and use advanced AI to compile and submit technical dossiers, minimizing delays. We help you navigate complex requirements like the TGA's UDI implementation, ensuring your products remain compliant from initial submission through post-market surveillance. Visit https://pureglobal.com or contact us at [email protected] to learn more. Explore our free AI tools and regulatory database at https://pureglobal.ai.

The European Commission has significantly expanded the list of 'well-established technologies' (WET) under the EU Medical Devices Regulation (MDR) as of June 29, 2026. This episode details the two new Delegated Regulations, explaining how this change exempts dozens of additional Class III and implantable devices—including certain catheters, bone fillers, and spinal fixation systems—from the default requirement to conduct clinical investigations. We explore the practical implications for manufacturers, including how to leverage this exemption to save time and resources, what kind of evidence is required for justification, and how it streamlines conformity assessment for certain Class IIb devices. Key Questions: - What are 'well-established technologies' (WET) under the EU MDR? - Which new device types were added to the WET list on June 29, 2026? - How does the WET exemption affect clinical investigation requirements for Class III devices? - What does the updated rule mean for conformity assessment of Class IIb implantable devices? - Can manufacturers of newly listed WET devices avoid conducting new clinical trials? - What kind of evidence is needed to justify using the WET exemption? - How should you update your Clinical Evaluation Report (CER) for a WET device? - What are the immediate next steps for manufacturers of devices like spinal fixation systems or dental implants? - How should you approach discussions with your Notified Body about this change? Sources: - https://www.raps.org/news-and-articles/news-articles/2026/6/european-commission-expands-list-of-well-established-technologies-under-mdr - https://www.qbd.group/en/news/new-mdr-updates-for-well-established-technologies/ - https://www.emergobyul.com/news/wet-devices-legally-expanded-european-legislation - https://www.citeline.com/insights/eu-expands-mdr-wet-exemption-list How Pure Global can help: Pure Global provides expert regulatory consulting for MedTech and IVD companies navigating complex regulations like the EU MDR. Our team can help you determine if your device qualifies under the new Well-Established Technologies (WET) exemption, develop a robust clinical evaluation strategy, and compile the necessary technical documentation to justify your approach to Notified Bodies. By combining local expertise with advanced AI, we streamline your path to market access, saving you time and resources. For end-to-end support on regulatory strategy, dossier submission, and post-market compliance, visit us at https://pureglobal.com or contact us at [email protected]. Explore our free AI tools and device database at https://pureglobal.ai.

China's National Medical Products Administration (NMPA) has released its first-ever "Guiding Principles for the Classification of Brain-Computer Interface (BCI) Medical Devices" on June 30, 2026. This episode breaks down the new framework, explaining how the NMPA now classifies invasive and non-invasive BCI technologies based on risk and intended use. We cover the implications for manufacturers, detailing the pathways for Class II and Class III devices and providing actionable steps for regulatory, quality, and market-access teams to prepare for submission in China. Key Questions: - What are China's new classification rules for Brain-Computer Interface (BCI) devices? - How does the NMPA distinguish between invasive (Class III) and non-invasive (Class II/III) BCI technologies? - What makes a non-invasive BCI device Class II versus Class III under the new guidance? - What are the immediate steps foreign neurotech manufacturers should take to comply with Announcement No. 24? - How will this new framework affect the timeline and cost for BCI market entry in China? - What kind of clinical evidence will be required for high-risk BCI devices? - Why is a product's intended use now the most critical factor for BCI device classification in China? Sources: - https://www.jdsupra.com/legalnews/china-clarifies-medical-device-8356947/ How Pure Global can help: Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies seeking to enter complex markets like China. Our local experts and advanced AI tools streamline the entire market access process, from developing a regulatory strategy aligned with new guidance like the NMPA's BCI framework to compiling technical dossiers and managing submissions. We act as your local representative, ensuring ongoing compliance and post-market surveillance. Leverage our expertise to navigate the specific requirements for innovative devices and accelerate your product's journey to market. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and device database at https://pureglobal.ai.

The US FDA has announced a public meeting on July 22, 2026, to discuss the proposed recommendations for the sixth reauthorization of the Medical Device User Fee Amendments (MDUFA VI). This episode breaks down the MDUFA framework, explores the key proposed changes for fiscal years 2028-2032, and analyzes the impact on manufacturers. We cover potential changes to submission review timelines, new initiatives for digital health and AI/ML devices, and the expected adjustments to user fees, providing practical steps for regulatory teams to prepare. Key Questions: - What is MDUFA and why is its reauthorization critical for device manufacturers? - What are the key proposed changes for MDUFA VI covering fiscal years 2028-2032? - How might new performance goals impact 510(k) and PMA review timelines? - What new initiatives for digital health and AI/ML devices are being considered? - When is the public meeting and how can manufacturers provide input? - What are the potential financial implications of the proposed user fee structure? - How does MDUFA VI aim to enhance the pre-submission and post-market processes? - What practical steps should regulatory teams take now to prepare? Sources: - https://www.federalregister.gov/documents/2026/07/07/2026-14531/medical-device-user-fee-amendments-public-meeting-request-for-comments - https://www.fda.gov/news-events/cdrh-new-news-and-updates/july-7-2026-register-fdas-public-meeting-reauthorization-medical-device-user-fee-amendments How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping you navigate complex regulatory landscapes like the MDUFA reauthorization. Our experts develop efficient market access strategies, manage technical dossier submissions, and provide continuous regulatory monitoring to ensure your products remain compliant. By combining local expertise in over 30 markets with advanced AI tools, we streamline the registration process, saving you time and resources. Whether you're a startup or a multinational, we can help you prepare for MDUFA VI and accelerate your global expansion. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.